Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Inks $23M Debt Refinancing

NEW YORK (GenomeWeb) – Biodesix said today it has increased the size of its offering of Series G preferred shares in a follow-on sale, and has simultaneously entered a debt refinancing agreement with Innovatus Capital Partners for a $23 million term loan.

The company said it plans to use the additional capital to fund development of blood-based tests for guiding use of cancer immunotherapies, as well as to further the commercialization of its VeriStrat and GeneStrat lung cancer tests.

Biodesix also announced that Scott Hutton has joined the firm as chief operating officer. Hutton previously served as senior vice president and general manager of Spectranetics. Before that he was vice president and general manager of Medtronic's neurosurgery unit.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.